Treatment
68Ga-DOTATATE clinical trials
We’re tracking 13 recruiting studies that include 68Ga-DOTATATE, each written for real people, not researchers, below.
Recruiting studies
- NCT04559217RecruitingPhase 2
68Ga-DOTATATE PET/CT for neuroblastoma imaging
This study tests how well a new PET/CT scan using 68Ga-DOTATATE can find neuroblastoma. It’s for children and young adults who are being planned for a different scan (123I-MIBG) to compare imaging results.
Montreal, QuebecAges Up to 21 years - NCT06056362RecruitingPhase 1/Phase 2
Comparing new PET/CT tracers for neuroendocrine tumors
This study compares a new imaging agent (Al18F-NOTA-LM3) with two existing ones (68Ga-DOTATATE and 68Ga-NODAGA-LM3) during PET/CT scans to see if it's better at finding well-differentiated neuroendocrine tumors. Participating may help improve how these tumors are detected.
BeijingAges 18–80 - NCT06520319RecruitingPhase 1
Comparing two PET tracers for recurrent MTC
This study compares a new imaging agent called 68Ga-MGS5 with the standard agent 68Ga-DOTATATE to see which one better detects recurrent medullary thyroid carcinoma on a PET/CT scan. The goal is to improve tumor detection in people whose MTC has returned.
Fuzhou, FujianAges 18–80 - NCT02019706RecruitingPhase 2
PET/CT scans to find the cause of ectopic Cushing syndrome
This trial tests several special imaging scans to help doctors locate the source of hormone overproduction in ectopic Cushing syndrome. It may help confirm where the problem is so treatment can be better targeted.
Bethesda, MarylandAges 18–80 - NCT06226987Recruiting
Heart imaging study for Fabry disease
This study uses special MRI scans to look at how Fabry disease affects the heart. It may help researchers understand the disease better.
Cambridge, CambridgeshireAges 18 years+ - NCT07366099Recruiting
Special PET scan for tumor-induced osteomalacia
This trial tests a new PET/CT scan (using a tracer called Al18F-NOTA-LM3) to better find tumors causing TIO, a condition that leads to bone softening and weakness. It may help doctors diagnose and treat TIO more accurately.
Beijing, Beijing MunicipalityAges 18–80 - NCT04073797Recruiting
PET scan study of inflammation and cholesterol-lowering treatment
This study uses PET/CT and related scans to measure inflammation in artery plaque and how cholesterol-lowering treatment changes it. It may help researchers understand which treatments reduce artery inflammation for people with heart or blood-vessel disease and high LDL (“bad”) cholesterol.
CambridgeAges 18–99 - NCT05069220RecruitingEarly Phase 1
PET/CT scan to study neural crest tumors
This early-phase trial uses a special PET/CT scan to help evaluate neural crest tumors, which include conditions like neuroblastoma. It may help doctors understand how well the scan shows tumor activity to guide diagnosis and treatment planning.
Beijing, DongchengAges 1–80 - NCT06479811RecruitingPhase 1
Radioactive drug for advanced neuroendocrine and other cancers
This trial tests a new radioactive drug, [212Pb]VMT-Alpha-NET, that targets a protein on certain cancer cells. It is for people with specific types of advanced cancers that have gotten worse and are not responding to standard treatments.
Bethesda, MarylandAges 18–120 - NCT06500065Recruiting
Testing a new PET scan for soft tissue sarcoma
This study uses a special PET/CT scan (68Ga-DOTATATE) to see if it can better find soft tissue sarcomas. You will also have a standard PET/CT scan for comparison, and the results may help guide your treatment.
Columbus, OhioAges 18 years+ - NCT07284589RecruitingPhase 2
Ultralow dose pet scan for certain tumors
This trial tests a new way to take PET scan pictures using a very low amount of a radioactive tracer that targets a protein called SSTR2. It is designed to see if these scans can work well while reducing radiation exposure for patients with certain types of tumors.
Englewood, New JerseyAges 18–120 - NCT07288931Recruiting
PET/CT Scan for Pheochromocytoma and Paraganglioma
This trial uses a special PET/CT scan called Al18F-NOTA-LM3 to help doctors see pheochromocytoma and paraganglioma tumors more clearly. It may help find out if you have these tumors and guide your treatment.
Beijing, Beijing MunicipalityAges 18–80 - NCT06427798RecruitingPhase 1/Phase 2
Radioactive drug for previously treated gut or adrenal tumors
This trial tests a new radioactive drug, [212Pb]VMT-alpha-NET, that targets a receptor found on some tumor cells. It is for people with certain gut or adrenal gland tumors that have already been treated with a similar therapy but are still growing.
Bethesda, MarylandAges 18–120
What 68Ga-DOTATATE is being studied for
Conditions with recruiting 68Ga-DOTATATE studies.
Common questions
- Are there clinical trials studying 68Ga-DOTATATE?
- Yes. Clin2 currently lists 13 recruiting studies that include 68Ga-DOTATATE, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a 68Ga-DOTATATE trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is 68Ga-DOTATATE an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether 68Ga-DOTATATE or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.